PRA1 Activators
The class of PRA1 activators encompasses a diverse set of compounds that could potentially influence the function or regulation of PRA1 indirectly. This can be achieved through various mechanisms such as the disruption of Golgi function and vesicular transport by agents like Brefeldin A, Monensin, and Nocodazole. Similarly, inhibitors of protein kinases like Staurosporine, the PI3K inhibitor Wortmannin, and the mTOR inhibitor Rapamycin could potentially affect the pathways regulating PRA1.
Additionally, compounds that can inhibit protein synthesis like Cycloheximide, RNA synthesis like Actinomycin D, or CRM1-dependent nuclear export like Leptomycin B, could potentially influence the activity of PRA1. Furthermore, agents that can disrupt membrane organization like Nystatin and Filipin III, or the prenylation of Rab GTPases like Manumycin A, could potentially affect PRA1 activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A is a fungal metabolite that disrupts the Golgi apparatus and vesicular transport, potentially affecting PRA1 activity. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Monensin is an ionophore that disrupts Golgi function, potentially affecting PRA1 activity. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Nocodazole is a microtubule-depolymerizing agent that can disrupt vesicular transport, potentially affecting PRA1 activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent PI3K inhibitor, which can affect many cellular processes, potentially including the regulation of PRA1. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases, which could potentially affect PRA1's regulatory pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an inhibitor of mTOR, a protein involved in vesicular trafficking, potentially affecting PRA1. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Cycloheximide is an inhibitor of protein synthesis, potentially affecting the expression of PRA1. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D is an inhibitor of RNA synthesis, potentially affecting the expression of PRA1. | ||||||
Leptomycin B | 87081-35-4 | sc-358688 sc-358688A sc-358688B | 50 µg 500 µg 2.5 mg | $107.00 $416.00 $1248.00 | 35 | |
Leptomycin B is an inhibitor of CRM1-dependent nuclear export, potentially affecting PRA1 activity. | ||||||
Nystatin | 1400-61-9 | sc-212431 sc-212431A sc-212431B sc-212431C | 5 MU 25 MU 250 MU 5000 MU | $51.00 $129.00 $251.00 $3570.00 | 7 | |
Nystatin is a sterol-binding antifungal agent that can disrupt membrane organization, potentially affecting PRA1 activity. | ||||||